Medicare patients who have the apolipoprotein (APOE)-e4 genotype, which is tied to an increased risk of Alzheimer’s disease, heart disease and stroke, do not incur higher hospital costs than those without the genotype, US researchers report. Currently, neither private insurers nor Medicare makes financial risk adjustment decisions based on whether or not their clients carry this genotype.
The present findings suggests that they should continue this practice, lead author Dr. Donald H. Taylor, from Duke University in Durham, North Carolina, told Reuters Health.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!